Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KA |
---|---|---|
09:32 ET | 10000 | 0.6035 |
09:34 ET | 225 | 0.61665 |
09:36 ET | 2000 | 0.5927 |
09:38 ET | 11256 | 0.582 |
09:39 ET | 160 | 0.582 |
09:43 ET | 203 | 0.582 |
09:45 ET | 200 | 0.6 |
09:48 ET | 500 | 0.598295 |
09:56 ET | 2000 | 0.5997 |
09:57 ET | 290 | 0.5823 |
10:01 ET | 1200 | 0.59105 |
10:03 ET | 8019 | 0.5839 |
10:06 ET | 2000 | 0.584 |
10:08 ET | 10474 | 0.5771 |
10:10 ET | 1000 | 0.577 |
10:12 ET | 951 | 0.577 |
10:24 ET | 5500 | 0.5695 |
10:26 ET | 1500 | 0.571 |
10:30 ET | 2000 | 0.594944 |
10:53 ET | 3592 | 0.5714 |
11:02 ET | 200 | 0.58 |
11:09 ET | 500 | 0.575 |
11:11 ET | 1000 | 0.5747 |
11:20 ET | 100 | 0.5778 |
11:27 ET | 1160 | 0.5737 |
11:29 ET | 200 | 0.5774 |
11:31 ET | 200 | 0.578 |
11:33 ET | 100 | 0.5747 |
11:44 ET | 100 | 0.58 |
11:54 ET | 1490 | 0.57735 |
12:02 ET | 2755 | 0.5737 |
12:03 ET | 525 | 0.5694 |
12:09 ET | 100 | 0.5779 |
12:25 ET | 3000 | 0.5694 |
12:27 ET | 884 | 0.57 |
12:36 ET | 499 | 0.58 |
12:38 ET | 14701 | 0.599199 |
01:10 ET | 439 | 0.5703 |
01:14 ET | 404 | 0.5704 |
01:28 ET | 320 | 0.5838 |
01:30 ET | 200 | 0.5838 |
02:27 ET | 160 | 0.58425 |
02:42 ET | 116 | 0.5843 |
02:47 ET | 5570 | 0.599199 |
02:49 ET | 458 | 0.5993 |
02:54 ET | 599 | 0.6 |
03:14 ET | 4334 | 0.6 |
03:21 ET | 5000 | 0.61 |
03:23 ET | 7868 | 0.590101 |
03:27 ET | 160 | 0.5975 |
03:43 ET | 928 | 0.6097 |
03:52 ET | 4907 | 0.6091 |
03:54 ET | 221 | 0.61 |
03:59 ET | 1902 | 0.61 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kineta Inc | 7.0M | -0.4x | --- |
Plus Therapeutics Inc | 7.1M | -0.4x | --- |
Petros Pharmaceuticals Inc | 4.4M | -0.1x | --- |
Stemtech Corp | 6.0M | -1.0x | --- |
Athersys Inc | 271.6K | 0.0x | --- |
Aeterna Zentaris Inc | 9.5M | -0.6x | --- |
Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a monoclonal antibody (mAb), immunotherapy targeting VISTA (V-domain Ig suppressor of T cell activation), and an anti-CD27 agonist mAb immunotherapy. KVA12123 may be an effective immunotherapy for many types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer (OC), renal cell carcinoma (RCC) and head and neck squamous cell carcinoma. It is also developing an anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The nominated lead candidate is a fully human mAb that demonstrates nanomolar (nM) binding affinity to CD27 in humans.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.0M |
---|---|
Revenue (TTM) | $5.4M |
Shares Outstanding | 11.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.16 |
EPS | $-1.43 |
Book Value | $0.28 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 1.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -288.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.